Markku Juhani Fagerlund

FIT Biotech Oy engages in the business of researching, developing, and manufacturing diagnostic laboratory tests and pharmaceutical products. The firm is also involved in marketing gene transport unit vector technology to be used as a gene transport mechanism in gene therapeutic applications. The company was founded on May 17, 1995 and is headquartered in Tampere, Finland.

Stick Tech Oy engages in the development, manufacture, and marketing of products for dental reinforcements. It offers everStickC&B, a glass fibre reinforcement for minimally invasive composite bridges. The company was founded in 1997 and is headquartered in Turku, Finland.

Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki.

BioSilta Ltd. provides cell culture technology for laboratory researchers. It develops different uses of enzyme and biocatalytic activity to advance cell culture technology across a range of product formats and bacteria. The company was founded by Peter Neubauer in 2007 and is headquartered in Oulu, Finland.

Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Inveni Secondaries Management Oy is a Venture Capital firm, a subsidiary of Inveni Capital Oy founded in 2007 by Markku Juhani Fagerlund. Inveni Secondaries Management Oy is headquartered in Helsinki.

Novel medical devices for minimal invasive cardiac valve surgery. Medtentia has completed preclinical validation for its first product. Investors Inveni Capital and Industrifonden will take the company through its clinical development phase. Early human trials have been completed successfully Q1 in 2009. Medtentia's technology is patented in USA and patent pending in Europe. Medtentia is a venture-backed medical device company focused on the development of minimally invasive and percutaneous heart valve repair and replacement devices on currently proven therapy. Medtentia will act on a global basis with its core activities and team located to Europe with main office in Helsinki Finland and in the Medicon Valley region of southern Sweden in Lund. Medtentia is currently developing a technology platform of products to enable rapid surgical mitral valve annulus repair and replacement, perform percutaneous mitral repair and replacement, leverage currently accepted therapeutic practice and reduce invasiveness, procedural time and morbidity.